ArticleCancer2019
Cognitive performance in survivors of breast cancer and markers of biological aging.
Article in Cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 2 syntheses or guidelines pooled it, 74 citations in OpenAlex.
- Long-Term Side Effects of Breast Cancer Treatments: A Systematic Review.The breast journal · 2026Pooled it
- Mapping self-awareness of cancer-related cognitive impairment: a scoping review of evidence, methods, and neurobiological correlates.Frontiers in neurology · 2025Pooled it
- Associations between MoCA screening-positive cognitive impairment, anxiety, depression, and quality of life in patients with oral cancer: a cross-sectional study in China.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Chemotherapy neurotoxicity and aging: Uncovering shared central nervous system pathologies and potential interventions.Neuro-oncology advances · 2026Review
- Molecular markers, mechanisms and metrics of biological aging: a scoping review.Frontiers in aging · 2026Review
- Predictive value ofFrontiers in oncology · 2026Article
- Epigenetic age acceleration, telomere length, and neurocognitive function in long-term survivors of childhood cancer.Nature communications · 2025Article
- Cognitive dysfunction in chemobrain: Molecular mechanisms and therapeutic implications.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2025Review
- Review
- Inflammation and dimensions of fatigue in women with early stage breast cancer: A longitudinal examination.Cancer · 2025Article
- Article
- Accelerated Aging in Cancer and Cancer Treatment: Current Status of Biomarkers.Cancer medicine · 2025Review
- Effect of Donepezil on Dimensions of Patient-Reported Cognitive Impairment in Breast Cancer Survivors: Secondary Analysis of the NCORP REMEMBER Trial (WF-97116).JCO oncology advances · 2025Article
- A scoping review evaluating physical and cognitive functional outcomes in cancer survivors treated with chemotherapy: charting progress since the 2018 NCI think tank on cancer and aging phenotypes.Journal of cancer survivorship : research and practice · 2024Article
- Doxorubicin-induced neurotoxicity differently affects the hippocampal formation subregions in adult mice.Heliyon · 2024Article
- The association of chemotherapy-induced peripheral neuropathy with reduced executive function in chemotherapy-treated cancer survivors: A cross-sectional study.Journal of geriatric oncology · 2024Article
- Design and methods of the mobile assessment of cognition, environment, and sleep (MACES) feasibility study in newly diagnosed breast cancer patients.Scientific reports · 2024Article
- Brain gray matter reduction and premature brain aging after breast cancer chemotherapy: a longitudinal multicenter data pooling analysis.Brain imaging and behavior · 2023Article
- Cancer-related cognitive impairment in racial and ethnic minority groups: a scoping review.Journal of cancer research and clinical oncology · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundBiological aging pathways accelerated by cancer treatments may be a mechanism for cognitive impairment in cancer survivors. The goal of the current study was to examine whether indicators of biological aging, namely elevated levels of DNA damage, reduced telomerase enzymatic activity, and shorter peripheral blood mononuclear cell (PBMC) telomere length (TL) would be related to cognitive function in a cohort of survivors of breast cancer.
methodsThe authors evaluated a cross-sectional sample of 94 women aged 36 to 69 years who were treated for early-stage breast cancer 3 to 6 years previously. Leukocyte DNA damage, PBMC telomerase enzymatic activity, PBMC TL, and the inflammatory marker soluble tumor necrosis factor receptor II (sTNF-RII) were determined from blood samples. Cognitive function was assessed using a neuropsychological test battery and self-report. Linear regression models examined the relationship between biological aging predictors and cognitive outcomes.
resultsBoth higher DNA damage and lower telomerase were found to be statistically significantly related to lower executive function scores adjusting for age, body mass index, race, years from treatment, and intelligence score (standardized coefficients [B], -0.23 and 0.30; all P values <.05). In addition, lower telomerase activity was associated with worse attention and motor speed scores (B values, 0.30 and 0.24; P <.05). sTNF-RII and TL were found to be unrelated to any of the neurocognitive domains.
conclusionsThe results of the current study suggest a significant association between measures of biological aging and objective measures of cognitive performance in survivors of breast cancer. Future prospective studies are needed to confirm a causal role of biological aging as a driver of declines in cognitive function after cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.